Summary
• Skye Bioscience (SKYE) shares rise 11.6% in pre-market trading to $0.9800 following a new collaboration agreement.
• The deal with Halozyme Therapeutics involves using ENHANZE® technology for obesity treatment development.
• Despite a significant decline over the past quarter and year, the stock shows a year-to-date increase of 17.1%.
SKYE Bioscience, Inc. (SKYE) is seeing a notable increase, trading at $0.9800, up 11.6% from its previous close of $0.8782 in pre-market activity. This movement comes after the announcement of a new global collaboration and license agreement that could enhance the company’s drug development strategies.
New Collaboration Agreement Sparks Investor Interest
This pre-market surge follows a collaboration announcement between Skye Bioscience and Halozyme Therapeutics, Inc. Under the terms of the agreement, Skye will utilize Halozyme’s ENHANZE® technology for the development and potential commercialization of a subcutaneous formulation of nimacimab, specifically targeting obesity treatment. This strategic partnership, disclosed earlier today, is poised to bolster Skye’s efforts in higher-dose, subcutaneous administration possibilities, a critical factor in their ongoing product development.
Market Performance Overview
In terms of broader performance metrics, SKYE’s averages paint a stark picture. The stock has shown a decrease of approximately 79.4% over the last quarter and a 66.9% decline on a yearly basis. However, it has shown some resilience with a year-to-date performance increase of 17.1%. Despite the overall struggle, the stock’s pre-market spike reflects renewed interest that could hint at a shift in trader sentiment.
Technical Analysis Snapshot
Technically, SKYE is navigating a challenging landscape with its 20-day simple moving average (SMA) indicating a deviation of -12.2%. The stock’s relative strength index (RSI) stands at 38.3, suggesting it may be approaching oversold conditions. Average trading volume over the last three months is at 857,942, while the average volume over the past ten days is at 662,921, indicating a healthy trading interest following this catalyzing announcement.
Closing Thoughts
With the latest collaboration agreement now reflected in trading, investors will be closely monitoring how SKYE’s volume and momentum develop in the next session.